Focus Rheums| ACR Convergence 2024 Previews

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Coding Corner Question

  |  Issue: October 2007  |  

A 65-year-old male diagnosed with chronic inflammatory demyelinating polyneuropathy is scheduled for a follow-up visit for an intravenous immune globulin (IVIg) infusion.

The patient advises the physician that he is also having minor joint pain in his left knee. The physician performs a detailed history and an expanded, problem-focused examination. The physician’s notes support medical decision-making of moderate complexity.

ADVERTISEMENT
SCROLL TO CONTINUE

The IVIg infusion duration is three hours and 38 minutes. The patient is infused with 25 grams of Octagam, and one 250-cc bag of normal saline is used to establish venous access. How should this office visit be coded?

Click here for the answer

ADVERTISEMENT
SCROLL TO CONTINUE

Related Articles

    The Mystery of IVIg

    Although initially given as replacement therapy for patients with primary and secondary immunodeficiency states, intravenous immunoglobulin (IVIg) has proven to be effective in the treatment of various autoimmune and inflammatory disorders. This success has led to a dramatic increase in the use of IVIg, with its use as an antiinflammatory agent now vastly surpassing its use in the treatment of immunodeficiencies. Even so, the basis for the antiinflammatory activity of IVIg remains unclear.

    MIA Studio / shutterstock.com

    Kawasaki Guideline Urges Treatment Intensification for Some Patients

    A soon-to-be published guideline from the ACR and the Vasculitis Foundation on Kawasaki disease underscores the importance of early diagnosis and intensified treatment for people with this serious condition.1 Intravenous immunoglobulin (IVIG) remains the treatment mainstay, and prompt, aggressive treatment may be able to reduce the risk of serious complications in some patients. The guideline…

    Exploring Kawasaki Disease

    New epidemiologic data, clinical studies have shed light on diagnosis, treatments, patient outcomes for this childhood disease, but etiology is still unknown

    Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…